2024 OBJECTIVE

Achieved to date
0%
10M€

10 years

For 10 years, Liryc has pursued a unique research approach that brings together the world’s leading experts. It gathers institutional and industrial players around the same objective: to better prevent and cure heart rhythm diseases. We are the only research institute in the world to dedicate all our work to these diseases and to improve our understanding of the heart’s electrical network. We are bio-electricians of the heart!

2024

We have an ambitious 2020-2024 strategic plan. With your support, it can become a reality. It includes major projects such as research programs for preventing sudden death and treating atrial fibrillation, creation of a cardiac bioengineering platform, acquisition of a latest-generation scanner and development of a graduate school for cardiac electrophysiology.

10 M€

At Liryc, we are committed to not only understanding, curing and preventing such diseases on a daily basis, but also disseminating our knowledge throughout the world. Our teams are up against some considerable challenges. €10 million are needed to reduce heart rhythm disorders.

There is still a lot to do, but together with your help we can move faster and succeed.

THE 3 AREAS OF RESEARCH

RESEARCH & CARE

ACCELERATE RESEARCH AND TREATMENTS

Recherches Soins
Innovations Technologiques
TECHNOLOGICAL INNOVATIONS

GIVE PERSONALIZED THERAPIES CONCRETE FORM

EDUCATION & TRAINING

SHARE OUR KNOWLEDGE AND EXPERTISE

Enseignement Formation

In the spotlight

journée mondiale du merci (4)

READ THE 2024 ANNUAL REVIEW OF THE CAMPAIGN

Thanks to your generosity, 2024 was marked by major advances in research on heart rhythm disorders and significant improvements in
Voir plus
accuracy

First Liryc Charity Gala Dinner

The first Liryc Charity Gala Dinner will be remembered as a moment of solidarity and commitment in support of the
Voir plus
10 09 signature abbott (40) ok

Signature of a fundraising agreement with Abbott

Liryc is proud to announce the signing of a fundraising agreement with Abbott, a long-time partner in scientific research. This
Voir plus